Recall Register

Drug recall: Pramipexole dihydrochloride extended release tablets, 0.75 mg, packaged in 30-count bottles, Rx only, Manufactured by…

Class III FDA enforcement event 80969. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed impurities/degradation specifications: Finished product contain a known product impurity about current specification levels.

Class III, in the words of FDA

a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences

Par Pharmaceutical, Inc. started this drug recall on 6 Sep 2018. The firm address in the FDA record is in Chestnut Ridge, NY. FDA put the recall in Class III. FDA event 80969 has 1 product record. The first FDA enforcement report date is 19 Sep 2018. The record gives the status Terminated, with the termination date 6 Dec 2019. 128 of the 367 drug events that started in 2018 have more product records. The median drug event of 2018 has 1 product record. The openFDA file has 367 drug events that started in 2018 and 343 that started in 2017.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

United States nationwide

Recalling firm

Par Pharmaceutical, Inc., Chestnut Ridge, NY.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 80969: product records
Recall numberProductQuantityClassStatusReport date
D-1185-2018Pramipexole dihydrochloride extended release tablets, 0.75 mg, packaged in 30-count bottles, Rx only, Manufactured by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 10370-252-1116,207 (bottles of 30 tablets)Class IIITerminated19 Sep 2018

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class III: The lowest of the three FDA recall classes.

The event in context

Drug events that started in 2018
367
Share of these events in Class III
29%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
11

Other events of the firm

Other FDA enforcement events of Par Pharmaceutical, Inc.
InitiatedProduct (first record)TypeClassRecords
10 Aug 2020BusPIRone Hydrochloride Tablets, USP 7.5 mg NDC# 49884-725-01DrugClass II1
30 Mar 2020Glycopyrrolate Tablets, USP 1 mg, 100-count bottle, Rx only, Dist. by: Par Pharmaceutical, Chestnut Ridge, NY, 10977, U.DrugClass II1
4 Mar 2020PrediniSONE Tablets, USP 5 mg, 48-count bottle, Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977, NDDrugClass III1
10 Feb 2020Frovatriptan Succinate Tablets, 2.5mg, packaged in 1 blister card of 9 tablets per carton, Rx Only, Manufactured by: AlmDrugClass III1
30 Apr 2019Mycophenolate Mofetil for Injection, USP 500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical ChestnDrugClass I1
5 Oct 2016Travoprost Ophthalmic Solution USP, 0.004%, a) 2.5 mL and b) 5 mL bottles, Rx only, FOR USE IN THE EYES ONLY, Made in InDrugClass II1
27 Sep 2016Gildess 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, USP), 21 count, (a) 3 blisters (NDDrugClass III5
26 Oct 2015Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct DrugClass III2
12 Feb 2015Mafenide Acetate, USP, For 5% Topical Solution, STERILE, Net Wt. 50 grams sterile powder per packet, Rx only, PAR PharmaDrugClass II1
24 Nov 2014HydrALAZINE Hydrochloride Tablets, USP 25 mg, 100 count bottle Rx only, Distributed by: Par Pharmaceutical Companies, InDrugClass II1

Par Pharmaceutical, Inc.: all 11 events

Official channels

Cite this page

Recall Register. FDA enforcement event 80969. https://recallregister.com/fda/iii/80969/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
10 Nov 2026
Newest FDA report date on the register
4 Nov 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: United States nationwide
What quantity of product is in FDA event 80969?
The FDA record gives this quantity: 16,207 (bottles of 30 tablets)
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2018 have the same class?
29% of the 367 drug events that started in 2018 are in Class III.